Related Experiment Video

Updated: Sep 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung

Alia Daoud1, Quincy S Chu1

  • 1Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.

Frontiers in Oncology
|October 17, 2017
PubMed

Insights

Researchers are identifying new targetable oncogenic drivers in lung cancer beyond EGFR and ALK. This review examines less common targets and their associated targeted therapies for non-small cell lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The discovery of targetable oncogenic drivers like EGFR mutations and ALK translocations has revolutionized non-small cell lung cancer (NSCLC) treatment.
  • Efforts are ongoing to identify additional, less common drivers in both squamous and non-squamous NSCLC.
  • While some targeted therapies show significant clinical benefit, others offer modest improvements.

Purpose of the Study:

  • To review less common targetable oncogenic drivers in non-small cell lung cancer.
  • To discuss the current status and clinical utility of targeted therapies for these drivers.

Main Methods:

  • Literature review of recent studies on oncogenic drivers in NSCLC.
  • Analysis of clinical trial data for targeted therapies.
  • Synthesis of information on emerging targets and their therapeutic implications.

Main Results:

  • Several less common oncogenic drivers in NSCLC have been identified.
  • Targeted therapies for these drivers are in various stages of development and clinical application.
  • The clinical benefit of these therapies varies, with some approved and others showing modest efficacy.

Conclusions:

  • Continued research into novel oncogenic drivers is crucial for advancing NSCLC treatment.
  • Personalized medicine approaches incorporating targeted therapies are expanding.
  • Further investigation is needed to optimize the use and efficacy of targeted therapies for a broader range of NSCLC patients.
Keywords:
advancedchromosomal rearrangementmutationsnon-small cell lung cancernovel

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...